Neuro disorders are the disorders of brain, spine and nerve cells. It occurs due to the faulty genes and by muscular dystrophy. Damage to the nerve cell or death of the nerve cell causes degenerative disorders such as Parkinson’s disease and Alzheimer’s disease. Diseases of the blood vessels that supply the brain include stroke, Injuries to the spinal cord and brain Seizure disorders, such as epilepsy Cancer etc. The persons suffering from Neuro disorders have poor judgment, relapsing of memory, Tremor, Loss of automatic movement, Speech changes, rigid muscle etc. So this conference will provide novel technologies in the development of Neurology and neuro disorders.

The market analysis of stroke and neurology represent the largest and untapped market in medicine sector. This estimated market analysis is based on probability of approval and sales of products in late stage development, demographic trends and marketing of product. Emerging markets once again helps to boost revenues. CNS therapeutics comprise approximately 15% of total pharmaceutical sales, nearly $30 billion worldwide.

An estimated annual economic costs of anxiety disorders, depression, and schizophrenia are $47 billion, $44 billion, and $33 billion per year approximately. The goal of this session is to understand the market Value & Growth of Neurology Drugs, Current economics cost of clinical research and development.

The global neurobiology market size was valued at USD 28.42 billion in 2016 and is predicted to grow at a CAGR of 3.1% over the forecast amount. High influencing aspects, like current brain recording investigation and investigation comes, neuroscience-based initiatives by management bodies, and technological advances in tools and algorithms that are required in neurobiology. Numerous steps are undertaken by the aid communities to require brain-related studies and innovations a step additional. For example, in 2014, University of Utah launched the “Neuroscience Initiative” in order to help alleviate the devastating effects of brain disorders. The initiative was created for extending the understanding of the significances of brain disorders on health and channelizing the information into advanced solutions for patient care. Constant summary of novel merchandise by key participants within the market to combat varied medicine disorders is predicted to spice up Y-O-Y growth of this market.

For example, in September 2015, Codman Neuro announced CODMAN CERTAS plus programmable valve, an MRI-resistant programmable valve with eight different pressure settings. This product was introduced hydrocephalus treatment. Furthermore, key factor that has accelerated the research studies in this arena is the growth in number of various malignant CNS disorders such as Parkinsonism and Alzheimer’s disease. As geriatric population is liable to varied central nervous systems associated disorders like schizophrenic disorder, Alzheimer’s, and Parkinsonism, with growth in older population, this market is anticipated to witness lucrative growth.

The market analysis of stroke and neurology represent the largest and untapped market in medicine sector. This estimated market analysis is based on probability of approval and sales of products in late stage development, demographic trends and marketing of product. Emerging markets once again helps to boost revenues. CNS therapeutics comprises approximately 15% of total pharmaceutical sales, nearly $30 billion worldwide.

Estimated annual economic costs of anxiety disorders, depression, and schizophrenia are $47 billion, $44 billion, and $33 billion per year approximately. The goal of this session is to understand the market Value & Growth of Neurology Drugs, Current economics cost of clinical research and development.

Ischemic stroke is caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries. According to a World Health Organization (WHO) estimate, around
17 million people die every year due to cardiovascular diseases. Heart attacks and strokes respectively account for the highest number of deaths due to cardiovascular diseases, globally. The statistics of the Centres for Disease Control and Prevention suggest that about 87% of all strokes are ischemic strokes. Stroke is one of the leading cause of long term disability, occurring at a higher rate in the old age population. Moreover, stroke leads to 1 out of every 20 deaths, costing around $35 billion to U.S. annually and higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.

The two major factors propelling the growth of the acute ischemic stroke diagnosis and treatment market are; large patient pools and a concerning rise in population at a higher risk of developing stroke in the near future. Rising incidence of diabetes along with heavy tobacco users and an increase in the ageing population are significant factors that determine the market growth. However, the high cost of treatment, lack of transparent reimbursement policies, and limited availability of expertise; are likely to restrict the market growth.

The global ischemic stroke diagnosis and treatment market is segmented on the basis of type and geography. According to type, the market is segmented into diagnostics and therapeutics. The diagnostic market is further segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Blood tests. The therapeutic market further segments into Tissue Plasminogen Activator Anticoagulant, Antiplatelet and Antihypertensive. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.

The report provides a comprehensive analysis of the current market and estimations through 2015-2021, which would enable the stakeholders to capitalize on prevailing market opportunities and an in-depth analysis of the key segments of the market demonstrate the types of therapeutics along with the diagnostics that currently used in the acute ischemic stroke market.

The main precept of the statistical surveying is to provide a comprehensive analysis of the current market and estimations through 2015-2021, which would enable the stakeholders to capitalize on prevailing market opportunities and an in-depth analysis of the key segments of the market demonstrates the types of therapeutics along with the diagnostics that currently used in the acute ischemic stroke market.

With the support of our organizing committee members, Dr. Brankia Vasiljevic, Consultant Neurologist, Department of Neurology, NMC Healthcare, UAE, we take the privilege in scheduling the upcoming event “3rd Annual Conference on Stroke and Neurological Disorders” for December 07-08, 2020 in Abu Dhabi, UAE.

Contact:

Lavera Valentin
Program Manager | Stroke Meet 2020
Mail id: strokemeet@memeetings.com
Phone No.: +1-201-380-5561 | Ext. No. 7007
WhatsApp No.: +44-7723584425